CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
MCS110 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03455764
NCT03455764Phase 2Completed
CompareCT.gov

A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition

Dana-Farber Cancer Institute·interventional·Posted Mar 7, 2018·Updated Jul 31, 2024

In Brief

A Phase 2 clinical trial evaluating MCS110, Dabrafenib, and 1 other intervention for Melanoma. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventions involved in this study are: * MCS110 * Dabrafenib * Trametinib

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMelanoma
CountriesUnited States
CollaboratorsNovartis

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 7, 2018
Enrollment StartSep 10, 2018
Primary CompletionSep 5, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 8.3 years ago

Interventions

MCS110drug

MCS110 is a colony-stimulating factor-1 (CSF-1) inhibitor. It is a human monoclonal antibody which binds CSF-1.

Dabrafenibdrug

Dabrafenib attack different proteins that promote the growth of cancerous cells

Trametinibdrug

Trametinib attack different proteins that promote the growth of cancerous cells